Why the study?
Does treatment including anthracyclines improve antitumour efficacy or increase cardiotoxicity compared to treatment without anthracyclines in children with childhood cancer?
Does treatment including anthracyclines improve antitumour efficacy or increase cardiotoxicity compared to treatment without anthracyclines in children with childhood cancer?
There is limited evidence from RCTs regarding the antitumour efficacy and cardiotoxicity of anthracyclines in childhood cancers, with only single trials available for most tumor types preventing definitive conclusions.
No takes yet. Share an insight, caveat, or question.
Supports omitting anthracyclines in ALL; confirms survival benefit in Wilms' tumour and Ewing's sarcoma but leaves cardiotoxicity assessment open.
Dalen et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: